Alnylam Pharmaceuticals, Inc.ALNY

Alnylam Pharmaceuticals discovers, develops, and commercializes RNA interference (RNAi) therapeutics. Its portfolio includes approved treatments ONPATTRO (hereditary transthyretin-mediated amyloidosis), GIVLAARI (acute hepatic porphyria), and OXLUMO (primary hyperoxaluria type 1). The pipeline targets genetic, cardio-metabolic, hepatic, CNS, and ocular disorders, with candidates like zilebesiran, fitusiran, and vutrisiran. Based in Cambridge, MA, Alnylam partners with Regeneron, Sanofi, Novartis, and others.